Barry, OppHub America Desk · · Source: yahoo-tickers-tape-movers
Tempus AI Stock Surges on Merck-Moderna Cancer Vaccine Trial Update
* Investors may monitor Tempus for continued momentum as its acquisition of Personalis progresses, potentially benefiting from the validation of Personalis's genomic technology in successful drug trials.
Based on reporting from yahoo-tickers-tape-movers.
Tempus AI (TEM) shares experienced significant gains this week, climbing 39.5% due to positive Phase 3 trial data from Merck and Moderna for their jointly developed cancer vaccine. This surge is linked to Tempus's pending acquisition of Personalis, the company behind the core genomic tumor-profiling technology, which is expected to close by early 2027. Despite the recent rally, the stock remains down 10% over the past year.
Market context for this story
As of: WeekendLoading quotes…
Informational only — not investment advice. Full markets →
$SPYSPDR S&P 500 ETF
TradingView
Live chart & market data via TradingView · OppHub classroom · Delayed or exchange real-time per TradingView data agreements · Not investment advice
$MRNAModerna
TradingView
Live chart & market data via TradingView · OppHub classroom · Delayed or exchange real-time per TradingView data agreements · Not investment advice
Educational TradingView charts — search any symbol in the widget. Confirm on /markets/SPY and related $MRNA, $MRK, $TEM. Not investment advice.
Related markets
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).
Tempus AI (TEM) stock posted substantial gains this week, with its share price climbing 39.5% amid positive developments in the broader pharmaceutical sector. This surge occurred while the S&P 500 declined 1.9% and the Nasdaq Composite fell 2.8%. The upward momentum for Tempus AI was primarily driven by a press release from Merck and Moderna concerning their cancer vaccine trial.
The trial update detailed Phase 3 results for a messenger ribonucleic acid (mRNA) vaccine combined with Merck's Keytruda immunotherapy. Patients receiving the combined treatment demonstrated significant benefits, including a diminished return and spread of cancer compared to those on Keytruda alone. Tempus AI's stock soared in response, largely attributed to its impending acquisition of Personalis, the developer of the genomic tumor-profiling technology central to the vaccine’s development. The acquisition, a binding agreement, is anticipated to close by late 2026 or early 2027.
The trial results are seen as a strong validation of Personalis's NeXT Platform, suggesting the acquisition could provide significant tailwinds for Tempus AI. The success in precision medicine and genomic diagnostics aligns with Tempus's long-term growth strategy.
Read the full story
Original reporting and related coverage — attribution links only, not paid recommendations.
Trade this story
Robinhood
Webull
Tradier
IBKR
Chart this story
TradingView
Broker and exchange buttons use invite / refer-a-friend links (rewards may be capped). Charting links (TradingView) are partner offers that may pay OppHub America a commission at no extra cost to you.
OppSHOP
Full OppSHOP →As an Amazon Associate, OppHub America earns from qualifying purchases. Shopping here helps keep the site free — at no extra cost to you. Disclosure
OppSHOP
Related to this story
* Investors may monitor Tempus for continued momentum as its acquisition
Shop related →
Investing books
Read the classics
Shop this pick →
Personal finance books
Run the household books
Shop this pick →
Trading notebooks
Write the thesis first
Shop this pick →
Monitor for charts
See every pane
Shop this pick →
Story playbook
A pre-built map of what to watch — stocks, ETFs, and educational next steps. Not personalized advice.
Snapshot date: August 23, 2026 at 8:01 AM ET
This playbook was built when the story published and is not live-updated. Prices, news, and risk can change after this date — treat it as a starting map, not a current trade ticket.
Story → money map
genomic oncology and mRNA cancer vaccines
Tempus AI stock jumped because a major cancer vaccine trial proved successful using technology made by a company Tempus is buying. People who invest in healthcare are excited about how this advanced genetic testing helps fight cancer.
What changed
Merck and Moderna announced positive Phase 3 cancer vaccine trial results, validating the genomic technology of Personalis, which Tempus AI is acquiring.
Who wins / who loses
Tempus AI and genomic diagnostic providers win on validation, while traditional single-drug immunotherapy developers without genetic profiling lag.
Time horizon
Think in terms of the next few weeks.
Confidence & best fit
medium confidence · Long-term investor, Active trader
Safer theme exposure (ETFs)
Baskets that own the theme without betting on one company.
Single stocks (higher risk)
Primary = closest to the story · Peers = same industry · Second-order = knock-on effects · Avoid = looks related but may be a trap
Primary
- $TEMWatch — track, don’t rush
Tempus AI stock jumped because of the news, so you should watch to see if the price keeps rising or settles down.
View $TEM chart → · End-of-day delayed data
Peer
- $MRKBuild slowly — only if it fits your plan
Merck makes the main cancer drug used in the successful trial, which could help boost their overall business.
View $MRK chart → · End-of-day delayed data
- $MRNAWatch — track, don’t rush
Moderna helped create the successful cancer vaccine, proving their technology works for more than just flu shots.
View $MRNA chart → · End-of-day delayed data
Options (education only)
No strikes or expiries — a framework for how traders might express the view. Options can expire worthless.
Beginners should skip options here because the stock just had a massive one-week jump and options are likely very expensive right now.
See options-friendly brokers →Income / OppHub America angle
Not a trade tip — ways to use the insight outside the market.
- Research positions in precision medicine, clinical data analytics, and genomic sequencing firms.
What would break this thesis
- Regulatory delays or termination of the Personalis acquisition agreement by Tempus AI.
What to do next on OppHub America
Saved playbooks stay on this device for now.
Important
Not financial advice. OppHub America playbooks are educational market maps only — not recommendations to buy, sell, or hold any security. Markets move fast; information can be wrong or outdated. Trade and invest at your own risk. Do your own research or consult a licensed advisor.
Based on reporting from yahoo-tickers-tape-movers.
Informational and educational only — not investment, financial, or legal advice. Disclosure
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).